HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rat Overload Particle Exposure Is Not Predictive For Humans, Analysis Finds

This article was originally published in The Rose Sheet

Executive Summary

An analysis of the National Toxicology Program's Draft Report on Talc finds the result of overload exposure to "poorly soluble, low toxigenic and non-genotoxic" particles in rats is not predictive for humans, according to Donald Dungworth, PhD, University of California.

You may also be interested in...



Further Talc Research Needed For Carcinogen Risk Assessment - NTP

Additional studies, such as those assessing the impact of low-dose and long-term exposure of non-asbestiform talc, are needed to provide an accurate carcinogen risk assessment of the ingredient, according to the National Toxicology Program.

Further Talc Research Needed For Carcinogen Risk Assessment - NTP

Additional studies, such as those assessing the impact of low-dose and long-term exposure of non-asbestiform talc, are needed to provide an accurate carcinogen risk assessment of the ingredient, according to the National Toxicology Program.

UVA, UVB "Reasonably Anticipated" To Be Human Carcinogens, NTP Rules

Ultraviolet A and B radiation are "reasonably anticipated to be human carcinogens based on limited evidence from studies in humans and evidence from studies in experimental animals," the National Toxicology Program's Board of Scientific Counselors ruled during its Report on Carcinogens Subcommittee meeting in Washington, D.C. Dec. 13-15.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel